三聚体APRIL CAR结合域靶向多发性骨髓瘤
该研究设计了一种基于三聚体APRIL的CAR,可同时靶向BCMA和TACI,克服单靶点BCMA CAR治疗后出现的BCMA逃逸变异。体外和体内实验显示,三聚体APRIL CAR较单体形式增强对BCMA和TACI的结合及抗骨髓瘤活性,为预防和治疗BCMA逃逸提供新策略。
要点
- 三聚体APRIL CAR可双特异性靶向BCMA和TACI,覆盖BCMA阴性骨髓瘤。
- 三聚体形式较单体增强抗原结合与CAR-T抗骨髓瘤活性。
- 该策略有望预防和治疗BCMA CAR治疗后的BCMA逃逸。
核心结论
- 三聚体APRIL为基础的CAR能有效靶向BCMA阳性和BCMA阴性多发性骨髓瘤,并可能预防及治疗BCMA逃逸。
研究设计与样本
- 研究设计并比较了基于三聚体与单体APRIL作为抗原结合域的CAR,在体外和体内评估其结合与抗骨髓瘤活性。
主要发现
- 三聚体APRIL格式较单体APRIL格式增强了与BCMA和TACI的结合及CAR-T对多发性骨髓瘤的体外和体内活性。
临床怎么用
- 双特异性三聚体APRIL CAR有望用于多发性骨髓瘤治疗,尤其针对BCMA逃逸风险的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells (CARTs) have shown tremendous potential for the treatment of certain B-cell malignancies, including patients with relapsed/refractory multiple myeloma (MM). Targeting the B-cell maturation antigen (BCMA) has produced the most promising results for CART therapy of MM to date, but not all remissions are sustained. Emergence of BCMA escape variants has been reported under the selective pressure of monospecific anti-BCMA CART treatment. Thus, there is a clinical need for continuous improvement of CART therapies for MM. Here, we show that a novel trimeric APRIL (a proliferation-inducing ligand)-based CAR efficiently targets both BCMA+ and BCMA- MM. Modeled after the natural ligand-receptor pair, APRIL-based CARs allow for bispecific targeting of the MM-associated antigens BCMA and transmembrane activator and CAML interactor (TACI). However, natural ligands as CAR antigen-binding domains may require further engineering to promote optimal binding and multimerization to adequately trigger T-cell activation. We found that using a trimeric rather than a monomeric APRIL format as the antigen-binding domain enhanced binding to BCMA and TACI and CART activity against MM in vitro and in vivo. Dual-specific, trimeric APRIL-based CAR are a promising therapeutic approach for MM with potential for preventing and treating BCMA escape.
引用
- Schmidts A, Ormhøj M, Choi BD, et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019. PMID: 31698455. doi:10.1182/bloodadvances.2019000703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。